Louisiana Healthcare Connections Policies and Procedures Updates
Date: 04/01/25
Louisiana Healthcare Connections is sharing with providers the below policies and procedures that were developed and/or revised; posted for public comment and approved by LDH in accordance with La. R.S. 46:460.54. Non-material revisions do not require LDH approvals.
Please share this notice with other members of your practice and office staff as necessary.
These guidelines will be implemented 30 days from the date of this notice and will be posted on our Clinical & Payment Policies page.
Policy & Procedure # | Policy & Procedure Title | New, material revisions, non-material revisions |
---|---|---|
LA.CP.CG.01 | CG Testing: Aortopathies and Connective Tissue Disorders | Material |
LA.CP.CG.02 | CG Testing: Cardiac Disorders | Material |
LA.CP.CG.03 | CG Testing: Dermatologic Conditions | Material |
LA.CP.CG.04 | CG Testing: Epilepsy, Neurodegenerative, and Neuromuscular Conditions | Material |
LA.CP.CG.05 | CG Testing: Eye Disorders | Material |
LA.CP.CG.06 | CG Testing: Gastroenterologic Disorders Non-Cancerous | Material |
LA.CP.CG.07 | CG Testing: General Approach to Genetic and Molecular Testing | Material |
LA.CP.CG.08 | CG Testing: Hearing Loss | Material |
LA.CP.CG.09 | CG Testing: Hematologic Conditions Non-Cancerous | Material |
LA.CP.CG.11 | CG Testing: Kidney Disorders | Material |
LA.CP.CG.12 | CG Testing: Lund Disorders | Material |
LA.CP.CG.13 | CG Testing: Metabolic, Endocrine, and Mitochondrial Disorders | Material |
LA.CP.CG.14 | CG Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay | Material |
LA.CP.CG.15 | CG Testing: Prenatal Cell-Free DNA Testing | Material |
LA.CP.CG.16 | CG Oncology: Cancer Screening | Material |
LA.CP.CG.17 | CG Oncology: Cytogenetic Testing | Material |
LA.CP.CG.18 | CG Testing: Preimplantation Genetic Testing | Material |
LA.CP.CG.19 | CG Testing: Prenatal and Preconception Carrier Screening | Material |
LA.CP.CG.20 | CG Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss | Material |
LA.CP.CG.21 | CG Testing: Skeletal Dysplasia and Rare Bone Disorders | Material |
LA.CP.CG.22 | CG Testing: Hereditary Cancer Susceptibility | Material |
LA.CP.CG.23 | CG Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies | Material |
LA.CP.CG.24 | CG Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) | Material |
LA.CP.CG.25 | CG Oncology: Algorithmic Testing | Material |
LA.CP.CG.26 | CG Testing: Pharmacogenetics (Version A) | Material |
LA.CP.CG.34 | CG Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders | Material |
LA.CP.MP.51c | Reduction Mammoplasty and Gynecomastia Surgery | Material |
LA.CP.MP.43 | Functional MRI | Material |
LA.CP.MP.26 | Articular Cartilage Defect Repairs | Material |